share_log

CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital International Investors(10.2%)

CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

CRISPR Therapeutics | SC 13G/A：超过5%持股股东披露文件(修正)
SEC announcement ·  04/10 12:02
Moomoo AI 已提取核心信息
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission on March 29, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing reveals that CII now beneficially owns 8,223,994 shares of CRISPR Therapeutics' common stock, which represents 10.2% of the company's total outstanding shares. This position is held solely by CII, with no shared voting or dispositive power reported. The address of CII's principal business office is located at 333 South Hope Street, 55th Floor, Los Angeles, CA 90071. The filing was certified by Jae Won Chung, Vice President and Associate Counsel of the Fund Business Management Group at Capital Research and Management Company, on April 10, 2024. The statement asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission on March 29, 2024, indicating a significant ownership stake in CRISPR Therapeutics AG. The filing reveals that CII now beneficially owns 8,223,994 shares of CRISPR Therapeutics' common stock, which represents 10.2% of the company's total outstanding shares. This position is held solely by CII, with no shared voting or dispositive power reported. The address of CII's principal business office is located at 333 South Hope Street, 55th Floor, Los Angeles, CA 90071. The filing was certified by Jae Won Chung, Vice President and Associate Counsel of the Fund Business Management Group at Capital Research and Management Company, on April 10, 2024. The statement asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of CRISPR Therapeutics.
资本研究与管理公司旗下的资本国际投资者（CII）已于2024年3月29日向美国证券交易委员会提交了其附表13G的修正案，表明CRISPR Therapeutics AG拥有大量所有权。该文件显示，CII现在实益拥有CRISPR Therapeutics普通股的8,223,994股，占该公司已发行股票总额的10.2％。该职位仅由CII担任，未报告共享投票权或决定权。CII主要业务办公室的地址位于加利福尼亚州洛杉矶南希望街333号55楼 90071。该文件于2024年4月10日由资本研究与管理公司基金业务管理组副总裁兼助理法律顾问Jae Won Chung认证。该声明称，这些股份是在正常业务过程中收购的，不是为了改变或影响CRISPR Therapeutics的控制权。
资本研究与管理公司旗下的资本国际投资者（CII）已于2024年3月29日向美国证券交易委员会提交了其附表13G的修正案，表明CRISPR Therapeutics AG拥有大量所有权。该文件显示，CII现在实益拥有CRISPR Therapeutics普通股的8,223,994股，占该公司已发行股票总额的10.2％。该职位仅由CII担任，未报告共享投票权或决定权。CII主要业务办公室的地址位于加利福尼亚州洛杉矶南希望街333号55楼 90071。该文件于2024年4月10日由资本研究与管理公司基金业务管理组副总裁兼助理法律顾问Jae Won Chung认证。该声明称，这些股份是在正常业务过程中收购的，不是为了改变或影响CRISPR Therapeutics的控制权。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息